Therapeutic potential of serotonin antagonists in depressive disorders

Expert Opinion on Investigational Drugs
Martyn D WoodJeannette M Watson

Abstract

Although the precise neurochemical imbalances in depression are still unknown, a role for the neurotransmitter 5-hydroxytryptamine (serotonin) has been implicated since the identification of the first effective antidepressants, imipramine and iproniazid. This led to the development of the selective serotonin re-uptake inhibitors which are widely used in the treatment of depression and depressive disorders, including generalised anxiety disorder, social phobia, obsessive compulsive disorder etc. Studies involving chronic administration in rats led to the hypothesis that the different classes of antidepressant treatment produce a common neuroadaptive change, namely an enhancement of serotonin neurotransmission, albeit via different pre and postsynaptic mechanisms. From this, it was suggested that serotonin antagonists should induce similar neuroadaptive changes, either directly or through a potentiation of other antidepressant agents. Here, the profiles of novel serotonin antagonists currently in preclinical development are reviewed and their therapeutic potential is assessed.

References

Jul 1, 1979·Physiological Reviews·B Rusak, I Zucker
Nov 1, 1967·The British Journal of Psychiatry : the Journal of Mental Science·A Coppen
May 1, 1972·Archives of General Psychiatry·A CoppenR Noguera
Jul 1, 1994·Trends in Pharmacological Sciences·P Blier, C de Montigny
Aug 1, 1995·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J J MannJ Keilp
Jan 1, 1996·Behavioural Brain Research·M SkingleM B Tyers
Oct 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·L RomeroP Blier
Mar 19, 1997·European Journal of Pharmacology·G D BartoszykH Ziegler
Jan 14, 1998·Nature Medicine·J J Mann
Feb 24, 1998·Journal of Clinical Psychopharmacology·M NarayanJ C Nelson
Oct 17, 1998·British Journal of Pharmacology·J V SelkirkG W Price
Mar 3, 1999·Journal of Medicinal Chemistry·C KikuchiM Koyama
Mar 12, 1999·Neuroscience and Biobehavioral Reviews·J Menard, D Treit
Aug 5, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·P Blier, C de Montigny
Aug 12, 1999·European Journal of Pharmacology·D N MiddlemissG W Price
Aug 24, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·U L MullinsA S Eison
Feb 9, 2000·Trends in Pharmacological Sciences·P VanhoenackerJ E Leysen

❮ Previous
Next ❯

Citations

Mar 8, 2011·Expert Review of Neurotherapeutics·Carey D BalabanJoseph M Furman
Apr 1, 2003·Expert Opinion on Investigational Drugs·Frank P BymasterPierre V Tran
Jun 1, 2010·Brain Research·Seong-Ki Ahn, Carey D Balaban
Nov 1, 2006·Bioorganic & Medicinal Chemistry Letters·Dieter HamprechtMartyn Wood
May 25, 2004·Journal of Chemical Information and Computer Sciences·Alban LepailleurSylvain Rault

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.

Related Papers

Fundamental & Clinical Pharmacology
Sónia A SilvaCarlos A Fontes Ribeiro
Proceedings of the National Academy of Sciences of the United States of America
P B HedlundJ G Sutcliffe
Otology & Neurotology : Official Publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
Joseph M FurmanR G Jacob
© 2022 Meta ULC. All rights reserved